Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of CBP/β-catenin inhibitor OP-724 in HIV/HCV-related liver cirrhosis with hemophilia
jRCT2031200266Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foscenvivint in Cirrhosis, human immunodeficiency virus infection (HIV), hepatitis C virus infection and 1 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Occurrence rate of serious adverse events related to OP-724. Started Mar 2021; status: completed.
02
Drugs
foscenvivint
03
Conditions
Cirrhosishuman immunodeficiency virus infection (HIV)hepatitis C virus infectionhemophilia
Beyond the preview
Go deeper on jRCT2031200266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200266.